Dexcom CGM is associated with improved renal outcomes in people with diabetes on insulin and chronic kidney disease (CKD)

Dexcom CGM is associated with a 14% reduction in the rate of CKD progression among adults with CKD using insulin over 3 years. At 3 years, 24.8% of Dexcom CGM users experienced CKD progression vs. 34.8% of CGM non-users. This study highlights the benefits of Dexcom CGM in reducing kidney disease progression in alignment with recent expert consensus statements supporting CGM use in individuals with CKD.